Anderson Clinical Research

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Depression8 trials
• Alzheimer disease6 trials
• Migraine2 trials
• Insomnia1 trial

Phase

• Phase 311 trials
• Phase 210 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed11 trials
• Recruiting6 trials
• Terminated4 trials
• Active, not recruiting2 trials

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Eli Lilly and Company3 trials
• Otsuka Pharmaceutical Development & Commercialization, Inc.3 trials
• AEON Biopharma, Inc.2 trials
• Biogen2 trials
• and 6 more

Running trials

• Recruiting

  A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

  NCT07767903· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

  Contact: Anderson (principal investigator)

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  NCT07115329· Phase 2· Syndeio Biosciences, Inc· Source

  Contact: Donald A

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Bristol-Myers Squibb· Source

  Contact: Donald Anderson, Site 0008

• Recruiting

  Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

  NCT06480383· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Alzheimer disease1 recruiting
• Insomnia1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

  NCT07193563· Phase 2· Engrail Therapeutics INC· Source

• Completed

  A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

  NCT06785012· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

  NCT05749055· Phase 2· Engrail Therapeutics INC· Source

• Completed

  A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

  NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

  NCT05016661· Phase 2· AEON Biopharma, Inc.· Source

• Terminated

  Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

  NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source

• Completed

  Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

  NCT04845178· Phase 2· AEON Biopharma, Inc.· Source

• Completed

  Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

  NCT04641143· Phase 3· Biohaven Pharmaceuticals, Inc.· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source